Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parallelized droplet microfluidic mechanoporation enables robust and clogging-resistant intracellular gene delivery.

Microsystems & nanoengineering·2026
Same author

Safe and Efficient CRISPR Genome Editing of Primary Human T Cells Using a Droplet-Based Cell Mechanoporation Platform.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Fractal-shaped droplet microfluidics for highly scalable cell mechanoporation.

Lab on a chip·2025
Same author

Label-Free Leukocyte Biophysical Profiling Using Impedance-Deformability Cytometry for Rapid Cardiovascular Risk Stratification.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Microfluidics and nanofluidics for immunotherapy.

Biomicrofluidics·2025
Same author

Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Related Experiment Video

Updated: Jul 6, 2025

Flotation-Based T Cell Isolation, Activation, and Expansion from Human Peripheral Blood Mononuclear Cell Samples Using Microbubbles
06:37

Flotation-Based T Cell Isolation, Activation, and Expansion from Human Peripheral Blood Mononuclear Cell Samples Using Microbubbles

Published on: December 23, 2022

2.6K

Expanding CAR-T cell immunotherapy horizons through microfluidics.

Hyelee Kim1,2, Suyeon Kim1,2, Hyunjung Lim2

  • 1Department of Bioengineering, Korea University, 02841 Seoul, Republic of Korea.

Lab on a Chip
|January 4, 2024
PubMed
Summary

Microfluidics can improve chimeric antigen receptor (CAR)-T cell therapy manufacturing for cancer. This technology addresses challenges in scalability and cost, enhancing CAR-T cell production for broader applications.

More Related Videos

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.1K

Related Experiment Videos

Last Updated: Jul 6, 2025

Flotation-Based T Cell Isolation, Activation, and Expansion from Human Peripheral Blood Mononuclear Cell Samples Using Microbubbles
06:37

Flotation-Based T Cell Isolation, Activation, and Expansion from Human Peripheral Blood Mononuclear Cell Samples Using Microbubbles

Published on: December 23, 2022

2.6K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.1K

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy has shown success in treating blood cancers but faces limitations in solid tumor treatment, safety, and manufacturing scalability.
  • Current CAR-T cell production methods are complex, costly, and difficult to scale, hindering wider clinical application.
  • Microfluidic technologies offer potential solutions to these manufacturing challenges due to their efficiency and automation capabilities.

Purpose of the Study:

  • To provide a comprehensive review of CAR-T cell manufacturing processes.
  • To identify challenges in current CAR-T cell production.
  • To explore the application of microfluidics in overcoming these challenges and advancing cell-based therapies.

Main Methods:

  • Review of existing literature on CAR-T cell manufacturing and microfluidic technologies.
  • Analysis of the step-by-step CAR-T cell production process.
  • Discussion of microfluidics integration and its impact on efficiency, scalability, and cost-effectiveness.

Main Results:

  • Microfluidics can streamline CAR-T cell manufacturing, improving efficiency and scalability.
  • Integration of microfluidics addresses key challenges in CAR-T cell production, including safety and cost.
  • Microfluidics-based approaches show promise for next-generation CAR constructs and allogeneic cell therapies.

Conclusions:

  • Microfluidics integration is a promising strategy to enhance CAR-T cell therapy manufacturing.
  • This technology can facilitate the development of CAR-T cell therapies for solid tumors and 'off-the-shelf' products.
  • Microfluidics holds significant potential for advancing cell-based cancer immunotherapies.